These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 19593824)
1. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Eisenstein SA; Holmes PV; Hohmann AG Synapse; 2009 Nov; 63(11):941-50. PubMed ID: 19593824 [TBL] [Abstract][Full Text] [Related]
2. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Eisenstein SA; Clapper JR; Holmes PV; Piomelli D; Hohmann AG Pharmacol Res; 2010 May; 61(5):419-29. PubMed ID: 20044005 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Spradley JM; Guindon J; Hohmann AG Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756 [TBL] [Abstract][Full Text] [Related]
5. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Thiemann G; van der Stelt M; Petrosino S; Molleman A; Di Marzo V; Hasenöhrl RU Behav Brain Res; 2008 Mar; 187(2):289-96. PubMed ID: 17988751 [TBL] [Abstract][Full Text] [Related]
6. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589 [TBL] [Abstract][Full Text] [Related]
7. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. Butler RK; Rea K; Lang Y; Gavin AM; Finn DP Pain; 2008 Dec; 140(3):491-500. PubMed ID: 19004548 [TBL] [Abstract][Full Text] [Related]
8. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Moise AM; Eisenstein SA; Astarita G; Piomelli D; Hohmann AG Psychopharmacology (Berl); 2008 Oct; 200(3):333-46. PubMed ID: 18545985 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. Forget B; Guranda M; Gamaleddin I; Goldberg SR; Le Foll B Psychopharmacology (Berl); 2016 May; 233(10):1823-8. PubMed ID: 26864774 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of fatty-acid amide hydrolyse (FAAH) exerts cognitive improvements in male but not female rats. Hlavacova N; Chmelova M; Danevova V; Csanova A; Jezova D Endocr Regul; 2015 Jul; 49(3):131-6. PubMed ID: 26238495 [TBL] [Abstract][Full Text] [Related]
11. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159 [TBL] [Abstract][Full Text] [Related]
13. The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release. Seillier A; Giuffrida A Neuropharmacology; 2018 Mar; 130():1-9. PubMed ID: 29169961 [TBL] [Abstract][Full Text] [Related]
14. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Haller VL; Stevens DL; Welch SP Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181 [TBL] [Abstract][Full Text] [Related]
15. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Hansson AC; Bermúdez-Silva FJ; Malinen H; Hyytiä P; Sanchez-Vera I; Rimondini R; Rodriguez de Fonseca F; Kunos G; Sommer WH; Heilig M Neuropsychopharmacology; 2007 Jan; 32(1):117-26. PubMed ID: 16482090 [TBL] [Abstract][Full Text] [Related]
16. Intravenous self-administration of amphetamine is increased in a rat model of depression. Holmes PV; Masini CV; Primeaux SD; Garrett JL; Zellner A; Stogner KS; Duncan AA; Crystal JD Synapse; 2002 Oct; 46(1):4-10. PubMed ID: 12211093 [TBL] [Abstract][Full Text] [Related]
17. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Cippitelli A; Cannella N; Braconi S; Duranti A; Tontini A; Bilbao A; Defonseca FR; Piomelli D; Ciccocioppo R Psychopharmacology (Berl); 2008 Jul; 198(4):449-60. PubMed ID: 18446329 [TBL] [Abstract][Full Text] [Related]
18. Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage. Vinkers CH; Breuer ME; Westphal KG; Korte SM; Oosting RS; Olivier B; Groenink L Neuroscience; 2009 Mar; 159(1):39-46. PubMed ID: 19136045 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate. Nallapaneni A; Liu J; Karanth S; Pope C Neurotoxicology; 2008 Nov; 29(6):1037-43. PubMed ID: 18765251 [TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. Schlosburg JE; Boger DL; Cravatt BF; Lichtman AH J Pharmacol Exp Ther; 2009 Apr; 329(1):314-23. PubMed ID: 19168707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]